Intestinal obstruction
Drug research and approvals for intestinal obstruction: what is recruiting, what Health Canada authorized, FDA orphan designations and EU medicines. See every condition.
As of Nov 21, 2026, 47 studies of intestinal obstruction are recruiting on ClinicalTrials.gov, and Health Canada has authorized 0 drug trials for it since 2013.
- Recruiting worldwide: 47
- Trials authorized in Canada: 0
- FDA orphan approvals: 0
- EU medicines: 0
- A Prospective Randomized Controlled Trial Comparing Primary Anastomosis and Bishop-Koop Procedure in the Management of…NCT07925814 · Not applicable · Alexandria University · starts May 1, 2026
- The Effect of Ostomy Care Education Applied With the Teach-Back Method to Ostomy-Opened Individuals on Self-Care Power,…NCT07788079 · Not reported · Saglik Bilimleri Universitesi · starts Sep 1, 2025
- The Value of Bowel Sounds in Evaluating Postoperative Intestinal Function Recovery in Colorectal Cancer PatientsNCT07705139 · Not reported · Zhongnan Hospital · starts Feb 1, 2026
- 18F-FTHA IMAGING OF THE INTESTINAL AND CENTRAL LYMPHATIC SYSTEMNCT07645573 · Early Phase 1 · University of Pennsylvania · starts Oct 10, 2025
- The Food Network EffectNCT07618559 · Not applicable · Casey Morehouse, DO · starts Jul 1, 2026
- Superior HypogastrIc plExus bLock During Laparoscopic Colorectal Cancer SurgeryNCT07579780 · Not applicable · Sixth Affiliated Hospital, Sun Yat-sen University · starts Dec 15, 2025
- The Effect of Nasogastric Tube Placement on Complications in Patients With Small Bowel Obstruction - the SBO-TUBE TrialNCT07574515 · Not applicable · University Hospital, Linkoeping · starts May 27, 2026
- Neonatal Intestinal Obstruction: Prenatal Factors and Postnatal OutcomesNCT07434596 · Not reported · Meyer Children's Hospital IRCCS · starts Mar 11, 2025
- Peripheral Autonomic Block (BAP) Plus Transversus Abdominis Plane Block (TAP) for Postoperative Analgesia After…NCT07388953 · Not applicable · Faculdade de Ciências Médicas de Minas Gerais · starts Feb 12, 2026
Phase 3 2
- NaloxoneOpioid receptors; mu/kappa/delta antagonist
- Diatrizoic acidDiagnostic agent
Phase 2 4
- LanreotideSomatostatin receptor 5 agonist
- MetoclopramideDopamine D2 receptor antagonist
- DexamethasoneGlucocorticoid receptor agonist
- OctreotideSomatostatin receptor agonist
Phase 1 or earlier 3
- LoperamideMu opioid receptor agonist
- SulfasalazineArachidonate 5-lipoxygenase inhibitor
- MethylnaltrexoneMu opioid receptor antagonist
How its trials ended
145 ClinicalTrials.gov studies of the condition, classified by TrialPanorama, partly automatically, so some labels are wrongOf the 29 whose ending is known, 31% met their primary endpoint, 3% missed it and 66% stopped early.
- Completed, result not reported5337%
- Status unknown3423%
- Ongoing2920%
- Stopped: other or unclear118%
- Met its primary endpoint96%
- Stopped: enrollment or feasibility75%
- Missed its primary endpoint11%
- Stopped: funding11%
Condition names come from Health Canada's trial database. Orphan designations and EU medicines are matched when their indication names the condition as whole words, so a broader or differently worded indication can be missed. Recruiting counts are live from ClinicalTrials.gov's own condition search, refreshed daily. ClinicalTrials.gov, Health Canada Clinical Trials Database, FDA orphan designations, EMA